europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

Achieving the Potential of Genome Editing: the Perspective of the European Biotech Industry

25/06/2019
POSITION PAPER

Achieving the Potential of Genome Editing: the Perspective of the European Biotech Industry

The European Union has a unique opportunity to create headroom for innovation and continued investment for the future by fostering and guiding forward a major scientific breakthrough - genome editing.

Genome editing is an umbrella term for a range of tools that enable changes at targeted sites in the genome of an organism. Applied worldwide by researchers in academia, governmental research institutions and industry, these innovations represent a promising next step in research towards beneficial uses in medicine, agriculture and the bio-economy aimed at addressing some of society’s grand challenges.

While researchers, academia, industry and regulatory authorities have in-depth understanding of genome editing in terms of the underlying science and resulting benefits and challenges, this knowledge has not yet been fully passed on to the general public.

To help respond to this need, EuropaBio, the voice of the biotech industry, has developed this paper to bring the latest views from the developers and users of genome editing tools and applications.

Public engagement and proportionate regulatory policies would help ensure that Europe, together with the rest of the world, can reap the great societal and economic benefits that genome editing can bring.

EuropaBio calls upon European decision-makers to create platforms to ensure consumer confidence and to provide regulatory clarity to enable innovation for developing products by genome editing methods. To this end, EuropaBio calls for:

■ an inclusive, fact-based platform for dialogue, information sharing and trust building to be set up by the European Commission that brings together the EU Member States, industry, public researchers, academia and civil society;

■ a risk-proportionate, predictable, science-based and non-discriminatory application of existing policy approaches allowing innovation to benefit European society and the environment.

We stand ready to contribute to these efforts with our broad expertise in genome editing as it applies to healthcare, bio-economy and agriculture.

Download the file below to read the full position paper.

Achieving the Potential of Genome Editing: the Perspective of the European Biotech Industry


Download
2019_06_G_PP_EuropaBio-Updated-genome-editing-paperDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more
01/03/2023

Vlad Olteanu new Healthcare Public Affairs Director at EuropaBio


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies